RMgmDB - Rodent Malaria genetically modified Parasites

Summary

RMgm-998
Malaria parasiteP. berghei
Genotype
TaggedGene model (rodent): PBANKA_0203100; Gene model (P.falciparum): PF3D7_0110600; Gene product: phosphatidylinositol-4-phosphate 5-kinase (PIP5K)
Name tag: triple-HA
Phenotype Fertilization and ookinete;
Last modified: 10 March 2014, 15:05
  *RMgm-998
Successful modificationThe parasite was generated by the genetic modification
The mutant contains the following genetic modification(s) Gene tagging
Reference (PubMed-PMID number) Reference 1 (PMID number) : 24594931
MR4 number
Parent parasite used to introduce the genetic modification
Rodent Malaria ParasiteP. berghei
Parent strain/lineP. berghei ANKA
Name parent line/clone P. berghei ANKA 2.34
Other information parent lineP. berghei ANKA 2.34 is a cloned, gametocyte producer line of the ANKA strain (PubMed: PMID: 15137943).
The mutant parasite was generated by
Name PI/ResearcherBrochet, M; Billker, O.
Name Group/DepartmentWellcome Trust Sanger Institute, Hinxton
Name InstituteWellcome Trust Sanger Institute, Hinxton
CityHinxton, Cambridge
CountryUK
Name of the mutant parasite
RMgm numberRMgm-998
Principal namePIP5K-HA
Alternative name
Standardized name
Is the mutant parasite cloned after genetic modificationNo
Phenotype
Asexual blood stageNot tested
Gametocyte/GameteNot tested
Fertilization and ookineteExpression of PIP5K-HA in ookinetes
OocystNot tested
SporozoiteNot tested
Liver stageNot tested
Additional remarks phenotype

Mutant/mutation
The mutant expressses a C-terminal HA-tagged version of PIP5K

Protein (function)
Enzymes in the inositol phospholipid biosynthetic pathway. Phosphorylated phosphatidylinositol lipids have important roles in vesicle trafficking and as a source of secondary messengers in signal transduction. Their biosynthesis from phosphatidyl-1D-myo-inositol (PI) is mediated by lipid kinases. The P. berghei genome encodes four putative lipid kinases to convert PI first to phosphatidylinositol 4-phosphate (PI4P) and then to phosphatidylinositol (4,5)- bisphosphate (PI(4,5)P2). Hydrolysis of the latter by a PI-specific phospholipase C (PI-PLC) gives rise to the secondary messenger inositol (1,4,5)-trisphosphate (IP3), which plays an important role in P. berghei gametocytes, where it is responsible for the mobilisation of Ca2+ from internal stores, leading to activation and gametogenesis.

To test whether the PKG-dependent phosphorylation of enzymes associated with phosphoinositide metabolism has a direct role in ookinete motility, an experimental genetics approach was used to infer the role of putative PI kinases. Both the putative PI4K (PBANKA_110940) and the putative PIP5K (PBANKA_020310) were unable to be genetically disrupted (unpublished data), suggesting these genes may be essential for asexual growth, although both loci could be modified.

Phenotype
Expression of PIP5K-HA in ookinetes

Additional information
The location of PIP5K-HA rapidly redistributed from the cell periphery to the ookinete cytosol in ookinetes when treated with 0.5 mM C2 (an inhibitor of PKG), supporting a direct link between PKG and phosphoinositide metabolism.

Other mutants
RMgm-997: Unsuccessful attempts to disrupt PIP5K
RMgm-996: Unsuccessful attempts to disrupt PI4K (PBANKA_110940)
RMgm-969: A mutant expressing a mutated form of PI4K (PBANKA_110940)
 


  Tagged: Mutant parasite with a tagged gene
Details of the target gene
Gene Model of Rodent Parasite PBANKA_0203100
Gene Model P. falciparum ortholog PF3D7_0110600
Gene productphosphatidylinositol-4-phosphate 5-kinase
Gene product: Alternative namePIP5K
Details of the genetic modification
Name of the tagtriple-HA
Details of taggingC-terminal
Additional remarks: tagging
Commercial source of tag-antibodies
Type of plasmid/constructPlasmid double cross-over
PlasmoGEM (Sanger) construct/vector usedYes
Name of PlasmoGEM construct/vector-
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Plasmid/construct sequence
Restriction sites to linearize plasmid
Selectable marker used to select the mutant parasitehdhfr/yfcu
Promoter of the selectable markereef1a
Selection (positive) procedurepyrimethamine
Selection (negative) procedureNo
Additional remarks genetic modificationNo details are provided for the PlasmoGEM vector used
Additional remarks selection procedure
Primer information: Primers used for amplification of the target sequences  Click to view information
Primer information: Primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Sequence Primer 3
Additional information primer 3
Sequence Primer 4
Additional information primer 4
Sequence Primer 5
Additional information primer 5
Sequence Primer 6
Additional information primer 6